Capsules: gelatinous firm No. 0; the capsule case – orange, a cover – black; capsule contents – the granulated powder from color, light yellow to white with slightly yellowish shade, have a slight specific smell (on 30, 50, 100, 200 or 300 capsules in plastic containers with covers from propylene or polyethylene of high pressure, on 1 container in a cardboard pack; on 10 capsules in blister strip packagings from aluminum foil and a polyvinyl chloride film, on 2, 3 or 5 packagings in a cardboard pack);
Lyophilisate for preparation of solution for intravenous administration: the lyophilized weight from light yellow till white color (on 2,5 g in the glass bottles hermetically corked by rubber bungs on 5 bottles in a cardboard pack complete with solvent – water for injections (5 ampoules on 10 ml) or on 5 or 10 bottles in a cardboard pack).

Active agents are a part of 1 capsule:

Phospholipids (Lipoid C 80) (the main component – phosphatidylsincaline of 73-79% (in terms of 100% substance)) – 65 mg;
Sodium glycyrrhizinate (trinatriyevy salt of glycyrrhizic acid) – 35 mg.

Auxiliary components: microcrystallic cellulose – 141,2 mg, calcium carbonate – 204,7 mg, calcium stearate – 0,9 mg, talc – 7,7 mg, colloid silicon dioxide (aerosil) – 5,5 mg, solid gelatin capsules – 96 mg [the case: titanium dioxide (E171) – 1%, dye a sunset yellow (E110) – 1%, gelatin – to 100%; lid: titanium dioxide (E171) – 0,2%, dye black iron oxide (E172) – 3,5%, gelatin – to 100%].

Active agents are a part of 1 bottle with lyophilisate for preparation of injection solution:

Phospholipids (Lipoid C 100) – 500 mg;
Sodium glycyrrhizinate (trinatriyevy salt of glycyrrhizic acid) – 200 mg.

Auxiliary component: a maltose – 1800 mg.

Indications to use

Alcoholic, medicinal, toxic damages of a liver;
Fatty degeneration of a liver (hepatosis);
Cirrhosis (along with other drugs);
Acute and chronic viral hepatitis (along with other drugs);
Psoriasis (along with other drugs);
Intoxications (injection solution);
Eczema, neurodermatitis (injection solution).

Contraindications

Anti-phospholipidic syndrome (capsules);
Pregnancy and the period of a lactation (because of insufficiency of data on safety and efficiency of drug for this category of patients);
Age up to 12 years (because of insufficiency of data on safety and efficiency of drug for this age category of patients);
Hypersensitivity to drug components.

Patients with portal and arterial hypertension should appoint Phosphogliv in the form of capsules with care.

Route of administration and dosage

Capsules
Phosphogliv is accepted inside, washing down with a small amount of liquid, it is more preferable – during food. It is not necessary to chew capsules.

Drug is recommended to accept 3 times a day on 2 capsules.

The average duration of a course – 3 months, if necessary it can be increased up to 6 months.

Injection solution
Phosphogliv is entered intravenously, previously having dissolved powder in water for injections of 10 ml. Introduction is carried out slowly.

The recommended dosing mode: daily 2 times a day (in morning and evening) on 10 ml for 10 days. Upon termination of a course pass to Phosphogliv reception inside. The general duration of a course is defined by the doctor.

Side effects

Capsules
Phosphogliv is, as a rule, transferred by patients well, side effects develop seldom or never, according to post-registration observation – < 1/10 000. Во время терапии могут возникать следующие нарушения:

Cardiovascular system: peripheral hypostases, tranzitorny (passing) increase in arterial pressure;
Alimentary system: discomfort in a stomach, dyspepsia in the form of nausea, an eructation, abdominal distentions;
Allergic reactions: difficulty of nasal breath, skin rash, cough, conjunctivitis.

At development of these side effects it is necessary to interrupt therapy and to consult at the doctor.

Injection solution

Allergic reactions: skin rash (at hypersensitivity) which passes independently after Phosphogliv cancellation;
Other (at introduction of the daily doses exceeding recommended): hypostases, delay of liquid and sodium, hypopotassemia, increase in arterial pressure. At emergence of these disturbances, depending on degree of their expressiveness, it is necessary to lower a daily dose and/or to apply Spironolactonum on 50-100 mg a day.

Special instructions

At increase in arterial pressure it is necessary to stop therapy and to see a doctor.

Medicinal interaction

Phosphogliv in the form of lyophilisate cannot be mixed with other solutions. For dissolution use only of water for injections is possible. Solution of glucose or normal saline solution of sodium chloride is forbidden to be used for drug cultivation.